Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data.
about
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Antidepressants, anxiolytics, and hypnotics in pregnancy and lactationDrugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risksAntidepressant use in pregnancy: a critical review focused on risks and controversiesFirst trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort studyBenzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy--an epidemiological study using validated EUROCAT data.Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.Antidepressant use in pregnancy and the risk of cardiac defectsSelective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects.Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence.Antidepressant use in pregnant and postpartum womenExposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy.Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysisTreatment of nonpsychotic major depression during pregnancy: patient safety and challengesThe Nordic health registers - an important source when evaluating the safety of antidepressants during pregnancy.Pharmacological treatment of unipolar depression during pregnancy and breast-feeding--a clinical overview.Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms.Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study.Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort studyEarly-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.Biologically based treatment approaches to the patient with resistant perinatal depression.The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathyThe problem of confounding in studies of the effect of maternal drug use on pregnancy outcome.Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review.The effects of depression and use of antidepressive medicines during pregnancy on the methylation status of the IGF2 imprinted control regions in the offspring.Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007.Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort studySelective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort StudiesSelective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark.Prenatal antidepressant exposure associated with CYP2E1 DNA methylation change in neonates.Algorithms to estimate the beginning of pregnancy in administrative databasesCombined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register studyThe risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.Cardiac dysfunction and prenatal exposure to venlafaxine.The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspringParoxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study
P2860
Q26741187-C382B0E6-28C0-462F-BDA9-BE8BF9717A60Q26795384-91888AD7-F70A-4106-8E31-C2DBC58A84AAQ26991704-A7C9D45A-D405-4E6D-8D7F-19FA92006911Q28281407-9B69535E-AC89-41BC-9299-93FC8DD7A115Q28540008-C5B8188D-BAF6-4CEF-8F3D-A4B1ABC038C5Q30251634-2C24C960-C1A8-4FE7-A87E-0D8F4172BE4FQ30855293-65B4747A-11DC-4C87-8C43-A1515DD2B855Q33521786-D291BE69-D82A-4699-8ECF-AC47F3FB0E3CQ33775616-5F40091C-F107-4600-9140-9D8E9A51C150Q33801507-25A070B6-FB39-4624-933D-2E43BAECE80EQ34047430-84099A02-C1BB-4036-BB90-BB47382718B4Q34068023-CBD9F6EA-8D4D-4922-8C74-21EAA5AB9C7FQ34073546-2B7E6882-32B6-4421-9875-3CF047FCEE62Q34144128-09E8D0DE-3C6B-4570-8324-F2C6502DB001Q34237681-96EC1DEB-40B9-45A0-88CE-A66A9D784363Q34240630-89962746-B465-40ED-B6D2-D9DBD98D9720Q34250131-98FD1F74-B110-45F4-8F44-802244619881Q34483257-DE9DB1AF-28A1-450D-BA24-C7CD025D7A11Q34516341-6419DA3C-9F77-4076-BDC9-819B94317DADQ34702282-825E872C-441D-4B7C-9C63-C630127EA1A7Q34714284-B64EA3EB-8239-41BD-B399-DE650797D175Q34799159-C7BDB1E0-8789-42B3-A112-5EA5E50EDED0Q34981937-E320BB90-8A60-4F43-B0E6-60415B76440CQ35541040-0C22E962-A224-44B1-B8D1-A2127B5098A5Q35583773-6DFC4EDE-264A-46F1-AF35-E85D4C53E16FQ35608879-64D063D2-8842-46BF-8B3F-8E41D9B4158EQ35608913-8AADE38E-C9BC-49FE-AE34-0B4088755DF6Q35640425-D64C3B72-E24A-483A-9B28-079609530381Q35670663-C3379B7F-8FF4-4216-8BFA-B95411F8F63CQ35794715-62D59C68-BE7E-46E8-988D-0E8D4F1C5CE0Q36045075-FBE4F5C3-FAD2-4311-BC5A-2DC83985C15EQ36141324-585AA3C1-5E99-4465-A307-9682D6CD1031Q36209588-A489C96C-3B0A-4F91-A011-2E3942AA44BDQ36213523-F44BEB37-0C21-455C-8550-222540B079D8Q36219433-A89077E8-0B45-4D38-9482-3A24A83093FEQ36649868-8F50D7E3-6E6E-4090-BAC5-9197FF7A0EB4Q36706789-7EF60151-953E-4200-8208-4565E623961BQ36797574-307D0AF6-8FA3-43AD-A455-C28FF96959F3Q36860205-44D41572-F8E1-4CAE-A432-AD4192AD5F14Q37142457-C27525E5-AB8D-40C2-B0E8-C778DF7ACA46
P2860
Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Major congenital malformations ...... population-based health data.
@ast
Major congenital malformations ...... population-based health data.
@en
type
label
Major congenital malformations ...... population-based health data.
@ast
Major congenital malformations ...... population-based health data.
@en
prefLabel
Major congenital malformations ...... population-based health data.
@ast
Major congenital malformations ...... population-based health data.
@en
P2093
P2860
P356
P1476
Major congenital malformations ...... population-based health data.
@en
P2093
Clyde Hertzman
Jaafar Aghajanian
Shaila Misri
Wayne Riggs
William Warburton
P2860
P356
10.1002/BDRB.20144
P577
2008-02-01T00:00:00Z